Immunicum AB Announces Carlos de Sousa as New CEO to take the Company to its Next Stage of Development
September 27 2016 - 2:30AM
Gothenburg, Sweden, September 27,
2016 - Immunicum AB (publ), a biopharmaceutical company pursuing to
develop sophisticated, safe and efficient therapeutic cancer
treatments with powerful and long lasting immune responses, today
announced the appointment of Carlos de Sousa as Immunicum's Chief
Executive Officer effective on October 1, 2016. Mr. de Sousa brings
more than 25 years of relevant experience in the international
pharmaceutical and biotech industries, including senior positions
at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron
Pharmaceuticals and, most recently, as Chief Business Officer at
Zealand Pharma in Denmark.
Mr. de Sousa has a long international career,
honing his expertise on the business side of the pharma/biotech
industry both in big pharma and the smaller biotech arenas. Prior
to Zealand Pharma, as Chief Business Officer at BBB Therapeutics,
Mr. de Sousa was instrumental in driving strategy design and
implementation for out-licensing of phase I and phase II compounds
and implementing the U.S. market and pricing research for the two
lead compounds.
His experience in leading and transitioning
companies from early clinical stage to bringing a product to market
is highlighted by his ability to build key partnerships and comes
to Immunicum with an extensive global network of contacts.
Mr. de Sousa is a Medical Doctor by training,
having earned his medical degree at School of Medicine, University
of Lisbon and holds an Executive MBA from the Stern School of
Business, New York University.
"We welcome Carlos's experience and leadership to
Immunicum," said Agneta Edberg, Chairman of the Board. "In his new
role as chief executive, he will be responsible for driving the
development of INTUVAX, and our other cancer immunotherapies, in
order to bring innovative therapeutic solutions to critical patient
needs and create a profitable business for Immunicum's
shareholders. His results-oriented approach and ability to think
strategically will play a pivotal role in the coming years while
helping us grow towards profitability".
Mr. de Sousa will replace Jamal El-Mosleh,
Immunicum's CEO since September 2007, who will now work with Mr. de
Sousa to assure a smooth and seamless transition.
"Immunicum has made significant progress since the
Company's inception and especially over the last few years, due, in
part, to the great efforts of our former CEO, Jamal El-Mosleh. We
are now in a very pivotal stage in the Company's existence and the
Board felt it was time to seek new competencies for the further
development and capitalization of our lead product INTUVAX. Jamal
El-Mosleh has achieved a lot during his tenure as CEO and we are
truly grateful for his efforts," continued Ms. Edberg, Chairman of
the Board, "We are unanimous in our excitement for the future of
Immunicum."
For more information, please
contact:
Agneta Edberg, Chairman of the Board,
Immunicum
Ph: +46 (0)70 555 75 18
Agneta.edberg@gmail.com
The company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers
for the treatment of tumor diseases. A phase II clinical trial for
the Company's most advanced product - INTUVAX® against kidney
cancer - has been initiated. The project portfolio contains
additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on
First North Premier. www.immunicum.se
The information in this press
release is disclosed pursuant to the EU Market Abuse Regulation.
The information was released for public disclosure through the
agency of the company's contact person on September 27, 2016 at
08:30 CET
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024